Arrestee Drug Abuse Monitoring (ADAM) Program in the United States, 2003 (ICPSR 4020)
Census of Juveniles in Residential Placement and Juvenile Residential Facility Census, 1997-2010 -- Concatenated Matched Data [United States] (ICPSR 27543)
Census of Juveniles in Residential Placement and Juvenile Residential Facility Census, 1997-2010 -- Concatenated Matched Facility-Level Data [United States] (ICPSR 27544)
Census of Juveniles in Residential Placement and Juvenile Residential Facility Census, 1997-2010 -- Concatenated Matched State-Level Data [United States] (ICPSR 27545)
The Community Vulnerability and Responses to Drug-User-Related HIV/AIDS, 1990-2013 [96 Metropolitan Statistical Areas, United States] (ICPSR 36575)
The Community Vulnerability and Responses to Drug-User-Related HIV/AIDS, 1990-2013 [96 Metropolitan Statistical Areas, United States] study (CVAR) was a research study of why large United States Metropolitan Statistical Areas (MSAs) vary over time in their vulnerability to HIV/AIDS among drug users and in MSA responses to HIV/AIDS. This collection contains estimates of HIV prevalence among people who injected drugs (PWID) and among sub-populations of PWID. This collection is comprised of ten datasets with differing amounts of variables and provides trend data that describe the following:
- Epidemiologic outcomes including population prevalence of PWIDs and Non-injecting drug users (NIDUs), and particularly their prevalence among youth; and, among PWIDs, HIV prevalence, late-diagnosis HIV cases, and AIDS incidence and mortality.
- Implementation of evidence-based drug-related interventions including drug abuse treatment, syringe exchange, HIV counseling and testing.
- Implementation of non-evidence-based drug-related interventions including incarceration and arrests of drug users.
The collection contains data on the MSA sub-populations including Black, Hispanic, White and "other" race categories. In addition, some statistics are presented in age range categories such as ages 15-29, 30-64 and 15-64.
Criminal Justice Drug Abuse Treatment Studies (CJ-DATS): A Comparison of Two Reentry Strategies for Drug Abusing Juvenile Offenders, 2003-2009 [United States] (ICPSR 30143)
Differences in the Validity of Self-Reported Drug Use Across Five Factors in Indianapolis, Fort Lauderdale, Phoenix, and Dallas, 1994 (ICPSR 2706)
Drug Use Trajectories: Ethnic/Racial Comparisons, 1998-2002 [United-States] (ICPSR 30862)
Experience of Violence in the Lives of Homeless Persons: The Florida Four City Study, 2003-2004 (ICPSR 20363)
Juvenile Residential Facility Census, 2000-2010 -- Concatenated Data [United States] (ICPSR 27542)
Juvenile Residential Facility Census, 2000-2010 -- Concatenated State-Level Data [United States] (ICPSR 27546)
Juvenile Residential Facility Census, 2000 [United States] (ICPSR 4672)
Juvenile Residential Facility Census, 2002 [United States] (ICPSR 23520)
Juvenile Residential Facility Census, 2004 [United States] (ICPSR 25282)
Juvenile Residential Facility Census, 2006 [United States] (ICPSR 25981)
Juvenile Residential Facility Census, 2008 [United States] (ICPSR 34402)
Juvenile Residential Facility Census, 2010 [United States] (ICPSR 34449)
Multi-Site Adult Drug Court Evaluation (MADCE), 2003-2009 (ICPSR 30983)
The Multi-Site Adult Drug Court Evaluation (MADCE) study included 23 drug courts and 6 comparison sites selected from 8 states across the country. The purpose of the study was to: (1) Test whether drug courts reduce drug use, crime, and multiple other problems associated with drug abuse, in comparision with similar offenders not exposed to drug courts, (2) address how drug courts work and for whom by isolating key individual and program factors that make drug courts more or less effective in achieving their desired outcomes, (3) explain how offender attitudes and behaviors change when they are exposed to drug courts and how these changes help explain the effectiveness of drug court programs, and (4) examine whether drug courts generate cost savings.
Offenders in all 29 sites were surveyed in 3 waves, at baseline, 6 months later, and 18 months after enrollment. The research comprises three major components: process evaluation, impact evaluation, and a cost-benefit analysis. The process evaluation describes how the 23 drug court sites vary in program eligibility, supervision, treatment, team collaboration, and other key policies and practices. The impact evaluation examines whether drug courts produce better outcomes than comparison sites and tests which court policies and offender attitudes might explain those effects. The cost-benefit analysis evaluates drug court costs and benefits.
Project RETAIN: Providing Integrated Care for HIV-Infected Crack Cocaine Users, Florida and Georgia, 2013-2015 (ICPSR 39792)
This Fast Release study is part of the Seek, Test, Treat and Retain (STTR) Collaboration Project, which involved over twenty studies in the fields of HIV and drug abuse. All files in the compressed zip package are released as deposited by the PI and were not further processed.
This study evaluated the efficacy of an integrated "Retention Clinic" in achieving virologic suppression among HIV-infected cocaine users.
Seek, Test, Treat and Retain (STTR) Collaboration Project Summary Files, 7 countries, 2010-2017 (ICPSR 39821)
This study is part of the Seek, Test, Treat and Retain (STTR) Collaboration Project involved over twenty studies in the fields of HIV and drug abuse. All studies were independently developed, but were chosen for the collaboration because they focused on one or more steps of the HIV treatment cascade: Seek, Test, Treat and Retain. As part of STTR Collaboration Project, the studies were grouped into Criminal Justice-related studies and Vulnerable Population-related studies. The data collected by these studies included twelve common domains (e.g., Demographic characteristics, Mental Health) in each of which a shared questionnaire or instrument was taken up by the studies and adapted to fit the study.
The data in this study focuses on adult respondents' health status and viral load involving HIV and HCV.